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a  b  s  t  r  a  c  t
Icosapent  ethyl  is a  high-purity  prescription  form  of eicosapentaenoic  acid  (EPA)  ethyl  ester  approved
at  a dose  of 4  g/day  as  an  adjunct  to diet  to reduce  triglyceride  (TG)  levels  in  adult  patients  with  severe
(≥500  mg/dL)  hypertriglyceridemia.  This  post-hoc  exploratory  analysis  examined  the relationship  of  icos-
apent  ethyl  dose  with  EPA  concentrations  in plasma  and  red  blood  cells  (RBCs)  across  3 clinical  studies—a
phase  1 pharmacokinetic  study  in healthy  adult  volunteers  and  2 pivotal  phase  3  studies  (MARINE  and
ANCHOR)  in  adult  patients  with  hypertriglyceridemia—and  examined  the  relationship  between  EPA
levels  and  TG-lowering  effects  in  MARINE  and  ANCHOR.  In all  3 studies,  icosapent  ethyl  produced  dose-
dependent  increases  in  the  concentrations  of  EPA  in  plasma  and  RBCs.  In both  MARINE  and  ANCHOR,  thesecosapent ethyl
harmacodynamics
riglycerides
dose-dependent  EPA  increases  correlated  with  the  degree  of  TG  level  lowering  (all  P<0.01).  In patients
with  high  TG  levels  (≥200  mg/dL)  and  treated  with  icosapent  ethyl  4 g/day,  the  end-of-treatment  plasma
and  RBC  EPA  concentrations  were  >170  g/mL  and  >70  g/mL,  respectively.  These  studies  support  icos-
apent  ethyl  as  producing  predictable  dose-dependent  pharmacokinetics/pharmacodynamics,  with  TG
level lowering  dependent  upon  icosapent  ethyl  dose  and EPA  concentrations  in  plasma  and  RBCs.
© 2016  The  Authors.  Published  by Elsevier  Inc. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Icosapent ethyl (Vascepa®; Amarin Pharma, Inc., Bedminster,
J) is a high-purity prescription form of eicosapentaenoic acid
EPA) ethyl ester approved by the Food and Drug Administration as
n adjunct to diet to reduce triglyceride (TG) levels in adult patients
ith severe (≥500 mg/dL) hypertriglyceridemia [1]. Epidemiolog-
cal and clinical data suggest that high TG levels are a risk factor
or atherosclerotic cardiovascular disease (ASCVD) [2]. Genetic data
lso support a role for elevated TG levels in the causal pathway
f ASCVD [3–12]. Compared with placebo, in the Multi-Center,
lacebo-Controlled, Randomized, Double-Blind, 12-week Study
ith an Open-Label Extension (MARINE) and ANCHOR pivotal stud-
es, icosapent ethyl signiﬁcantly reduced TG levels in adult patients
ith very high TG levels (TG ≥ 500 and ≤2000 mg/dL) in MARINE
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ttp://dx.doi.org/10.1016/j.prostaglandins.2016.07.007
098-8823/© 2016 The Authors. Published by Elsevier Inc. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and in statin-treated adult patients with high TG levels (TG≥200
and < 500 mg/dL) in ANCHOR [13,14]. In these studies, icosapent
ethyl also signiﬁcantly reduced the levels of other atherogenic lipid
and lipoprotein parameters compared with placebo (e.g., non-high-
density lipoprotein cholesterol, apolipoprotein B, apolipoprotein
C-III, very-low-density lipoprotein cholesterol, remnant lipopro-
tein cholesterol, and low-density lipoprotein [LDL] particles) and
decreased markers of inﬂammation (e.g., oxidized LDL  particles,
lipoprotein-associated phospholipase A2, and C-reactive protein)
[13–19].
While other omega-3 fatty acid products that contain both
EPA and docosahexaenoic acid (DHA) may  signiﬁcantly raise LDL
cholesterol (LDL-C) levels when administered to patients with
elevated TG levels [20–23], icosapent ethyl did not raise LDL-C
levels compared with placebo [13,14]. In addition to the effects
on lipids, which may  be expected to reduce ASCVD risk, other
hypotheses behind the ongoing Reduction of Cardiovascular Events
with EPA-Intervention Trial (REDUCE-IT; NCT01492361) are that
EPA, when added to a statin, may  favorably affect other steps in
atherosclerosis, including endothelial dysfunction, oxidative stress,
foam cell formation, inﬂammation, plaque formation and progres-
sion, platelet aggregation, thrombus formation, and plaque rupture
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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24,25]. It should be noted that icosapent ethyl is not approved
y the US FDA to reduce the risk of coronary heart disease; the
ffect of icosapent ethyl on the risk of cardiovascular mortality and
orbidity has not been determined.
In the MARINE and ANCHOR studies, 12 weeks of treatment with
cosapent ethyl 4 g/day or 2 g/day signiﬁcantly increased end-of-
reatment plasma EPA levels and the EPA/arachidonic acid (AA)
atio [26,27]. In the Japan EPA Lipid Intervention Study (JELIS),
thyl icosapentate 1.8 g/day (another highly puriﬁed prescription
PA ethyl ester, approved in Japan but not in the US) signiﬁcantly
ncreased plasma EPA levels and the EPA/AA ratio at the 5-year
ollow-up, and decreased risk of major coronary events by 19%
P = 0.011) [28]. In a phase 1 pharmacokinetic study of healthy vol-
nteers, plasma EPA concentration increased in a dose-dependent
ashion [29]. This may  be of clinical importance because ASCVD
isk seems to increase with decreased EPA plasma [28] and red
lood cell (RBC) membrane concentrations [30]. A low omega-3
ndex (the ratio of EPA plus DHA relative to other fatty acids in the
BC membrane) is a cardiovascular risk factor associated with poor
SCVD outcomes [31,32]. A lower plasma EPA/AA ratio is corre-
ated with a higher risk of atherosclerosis progression and adverse
ardiovascular outcomes [33–36]. Thus, both the dose of icosapent
thyl, as well as EPA plasma and RBC concentrations, may  provide
linically meaningful insight into the potential ASCVD beneﬁts of
cosapent ethyl. This analysis included data from the MARINE and
NCHOR studies as well as the pharmacokinetic phase 1 study in
ealthy volunteers. The intent was to explore the effects of icos-
pent ethyl on EPA concentrations in plasma and RBCs in response
o dose and the relationship to TG lowering across these 3 clinical
tudies.
. Materials and methods
.1. Study design
This post-hoc exploratory analysis examined pharmacokinetic
nd pharmacodynamic data from 3 clinical studies. The ﬁrst study
as an open-label, randomized, multidose, phase 1 pharmacoki-
etic study including a 14-day screening period followed by a
-week treatment period [29]. The study enrolled healthy, non-
moking volunteers aged ≥ 18 and ≤55 years with a body mass
ndex of > 18 and ≤30 kg/m2. Use of lipid-altering medications or
upplements was not allowed within 6 weeks prior to random-
zation until the end of the study. The study randomized eligible
ubjects (6 men  and 6 women per group) to icosapent ethyl 2 g/day
dministered as one 1-g capsule twice daily, icosapent ethyl 4 g/day
dministered as two 1-g capsules twice daily, icosapent ethyl
 g/day administered as two 1-g capsules once daily, or icosapent
thyl 2 g/day administered as two 0.5-g capsules twice daily. The
resent analysis includes data from the ﬁrst 2 groups.
The other 2 studies, MARINE and ANCHOR, were piv-
tal, phase 3, placebo-controlled, randomized, double-blind,
ulticenter studies, with details previously described [13,14].
rieﬂy, both studies had a 4- to 6-week lead-in period of
iet, lifestyle, and medication stabilization, with washout of
rohibited lipid-altering medications, followed by a 12-week,
ouble-blind treatment period. Patients aged ≥18 years with
ualifying lipid levels (TGs ≥ 500 mg/dL to ≤2000 mg/dL in
ARINE; TGs≥200 mg/dL to <500 mg/dL with statin-stabilized LDL-
 ≥40 mg/dL and ≤115 mg/dL in ANCHOR) entered the treatment
eriod and were randomized to receive icosapent ethyl 4 g/day
two 1-g capsules twice daily), icosapent ethyl 2 g/day (one 1-g
apsule and one matched placebo capsule twice daily), or placebo
two matched capsules twice daily). In MARINE, stable statin ther-
py with or without ezetimibe was permitted but not required.ipid Mediators 125 (2016) 57–64
ANCHOR required eligible patients to be at high risk for cardio-
vascular disease as deﬁned by the National Cholesterol Education
Program Adult Treatment Panel III guidelines [37] and to be receiv-
ing a stable dose of statin therapy (atorvastatin, rosuvastatin, or
simvastatin with or without ezetimibe).
Investigators instructed subjects in each study to take study
medication orally with or after their morning and evening meal,
and subjects agreed to maintain a stable diet and physical activity
level throughout the study. Eligible women had a negative urine
pregnancy test at screening, agreed to use an effective method of
contraception, could not be pregnant or breastfeeding, and could
not be planning on becoming pregnant during the study. Each study
was conducted in accordance with the principles originating in the
Declaration of Helsinki and in accordance with Good Clinical Prac-
tice and all applicable laws and regulations. An institutional review
board at each site approved the respective study protocol before
any subjects were enrolled at that site. All subjects provided written
informed consent.
2.2. Assessments
In the MARINE and ANCHOR studies, fasting baseline EPA mea-
surements were taken before the ﬁrst dose of study drug, and
fasting trough (minimum concentration [Cmin]) EPA concentrations
were based on measurements taken before the morning icosapent
ethyl dose at 12 weeks of treatment. For the time points relevant
to this analysis, fasting EPA measurements were taken in the phase
1 pharmacokinetic study before the morning icosapent ethyl dose
on the ﬁrst day (pre-treatment baseline) and at 28 days (pre-dose
trough EPA concentration).
These studies measured EPA concentrations in plasma and in
RBCs using a liquid chromatography-tandem mass spectrometry
(LC–MS/MS) method (Charles River Laboratories Ltd, Elphinstone
Research Center, Tranent, Edinburgh, Scotland) as previously
described [29]. Total plasma EPA comprised all EPA forms, including
unesteriﬁed EPA as well as that incorporated into phospho-
lipids, triacylglycerols, and cholesteryl esters, whereas EPA in
RBCs was from cell membranes, where it is mainly incorporated
into phospholipids. For these measurements, lipids were isolated
from plasma and RBC suspensions by acid/methanol/chloroform
extraction followed by centrifugation, and puriﬁed by isohex-
ane extraction and ﬁltration on a solid-phase extraction column
after conﬁrmed complete lipid hydrolysis and transmethylation
following an overnight incubation at 50 ◦C with acid/methanol.
Quantitation of EPA in each sample utilized linolenic acid as an
internal standard and a standard EPA calibration curve. The lower
limits of quantitation (LLOQ) were 10 g/mL for total plasma EPA
and 5 g/mL for total RBC EPA.
The MARINE and ANCHOR studies evaluated serum TG levels
as previously described [26], using enzymatic colorimetric tests
(Olympus AU2700 or AU5400 Analyzer, Olympus Center Valley, PA)
with calibration directly traceable to US Centers for Disease Control
reference procedures.
2.3. Data analysis
The phase 1 pharmacokinetic study determined EPA concen-
trations in plasma and RBCs for subjects in the per-protocol
population, which included all randomized subjects who com-
pleted the 28-day treatment period without any protocol violations
and who provided baseline and day 28 samples. The MARINE and
ANCHOR studies determined EPA concentrations for patients in the
intent-to-treat population (all randomized patients who took ≥ 1
dose of study drug and had valid baseline laboratory efﬁcacy mea-
surements and at least 1 post-randomization laboratory efﬁcacy
measurement) who had EPA values at baseline and at the week-12
other Lipid Mediators 125 (2016) 57–64 59
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Fig. 1. Mean fasting trough total EPA concentrations in plasma at baseline and at
end  of treatment with icosapent ethyl in the phase 1 PK study in healthy adult
volunteers (28 days) and in the MARINE and ANCHOR studies in adult patients
with hypertriglyceridemia (12 weeks). End of treatment was 4 weeks for the phase
1  PK study and 12 weeks in the MARINE and ANCHOR studies. Error bars rep-
resent standard deviations. EPA = eicosapentaenoic acid; MARINE = Multi-Center,
Placebo-Controlled, Randomized, Double-Blind, 12-week Study with an Open-Label
Extension; PK = pharmacokinetic; SD = standard deviation.
Fig. 2. Icosapent ethyl dose dependence of fasting plasma EPA concentrations in
the  phase 1 PK study in healthy adult volunteers (28 days) and in the MARINE
and ANCHOR studies in adult patients with hypertriglyceridemia (12 weeks).
Mean concentrations are based on baseline-subtracted trough concentrations
of  total EPA (change from baseline) at steady state. *In the PK study, there
was no placebo group but a value of zero was plotted as a point of refer-H.E. Bays et al. / Prostaglandins & 
ndpoint. If missing, the last-observation-carried-forward method
as used for the endpoint value. The EPA concentration analyses
ere considered descriptive and P values were calculated merely to
elp identify possible trends for hypothesis generation and a nomi-
al alpha level of 5% was used without multiplicity adjustment. For
ARINE, percent change from baseline in EPA concentration was
valuated using an analysis of covariance (ANCOVA) model with
xed effect terms including treatment, randomization stratiﬁcation
actors (gender and the use of statin therapy [used statin therapy,
id not use statin therapy]), and baseline value as a covariate. For
NCHOR, percent change from baseline in EPA concentration was
valuated using ANCOVA with ﬁxed effect terms including treat-
ent, randomization stratiﬁcation factors (gender, type of statin
atorvastatin, rosuvastatin, simvastatin] and presence of diabetes
present diabetes, past or no diabetes]), and baseline value as a
ovariate. MARINE and ANCHOR analyzed serum TG levels as pre-
iously described [26].
In MARINE and ANCHOR, outliers were identiﬁed within
ach treatment group as percent change values <Q1 − 1.5•IQR
r >Q3 + 1.5•IQR, where Q indicates quartile and IQR indicates
nterquartile range. Patients with outlier values were excluded
rom the analysis. In MARINE and ANCHOR, when plasma EPA val-
es were below the LLOQ of 10.0 g/mL, 5 g/mL was  imputed for
nalysis; when RBC EPA values were below the LLOQ of 5.00 g/mL,
.5 g/mL was  imputed for analysis. In the PK study, when plasma
r RBC EPA values fell below their respective LLOQs, they were set
o zero and included in the analysis.
The relationship between change from baseline to week 12 end-
oint in EPA concentration and percent change from baseline to
eek 12 endpoint in TG level was evaluated using a correlation
nalysis of individual patient data from MARINE and ANCHOR. As
he analysis for TG concentration was non-parametric and sum-
arized with medians as previously described [14], the Spearman
orrelation coefﬁcient was calculated. A P value < 0.05 was the pre-
peciﬁed alpha for signiﬁcance for exploratory analyses in MARINE
nd ANCHOR and was used in the present post hoc analyses.
. Results
.1. Study populations
Table 1 shows the demographics for each study. Reﬂective of
he populations in each study, mean age was lower in the phase
 pharmacokinetic study of healthy volunteers (37.4 years) than
n the patients from MARINE (52.9 years) and ANCHOR (61.4
ears). Mean body weight and BMI  were greater in ANCHOR and
ARINE patients than in the subjects in the pharmacokinetic study.
iabetes mellitus was present in 27.5% of patients in MARINE
nd 73.2% of patients in ANCHOR. Consistent with entry criteria,
aseline median TG levels were numerically higher in MARINE
679.5 mg/dL) than in ANCHOR (259.0 mg/dL) patients (Table 2).
aseline mean EPA concentrations in plasma and RBCs were also
umerically higher in the MARINE study than in the other 2 studies
Table 2).
.2. EPA dose response
Plasma trough total EPA concentrations at baseline and end-
f-treatment were available for 19 of 24 randomized subjects
79.2%) in the phase 1 pharmacokinetic study, 192 of the 229
andomized patients (83.8%) in MARINE, and 225 of the 702 ran-
omized patients (32.1%) in ANCHOR. Treatment with icosapent
thyl produced dose-dependent increases in plasma EPA concen-
ration in healthy volunteers (phase 1 pharmacokinetic study)
nd patients with hypertriglyceridemia (MARINE and ANCHOR)ence. CI = conﬁdence interval; EPA = eicosapentaenoic acid; MARINE = Multi-Center,
Placebo-Controlled, Randomized, Double-Blind, 12-week Study with an Open-Label
Extension; PK = pharmacokinetic.
(Fig. 1). In each of these 3 studies, icosapent ethyl 4 g/day produced
greater increases in plasma EPA concentration than for 2 g/day
both in plasma (Fig. 2) and RBCs (Fig. 3). In MARINE, the least
squares mean change ± SE from baseline to end of treatment in
plasma EPA was +269.2 ± 16.3 g/mL with icosapent ethyl 4 g/day,
+124.2 ± 16.8 g/mL with the 2-g/day dose, and −0.2 ± 17.1 g/mL
with placebo; the corresponding least squares mean changes in RBC
EPA concentrations were +57.0 ± 2.7 g/mL, +30.6 ± 2.8 g/mL, and
−1.4 ± 2.8 g/mL, respectively (P < 0.0001 for each icosapent ethyl
dose vs placebo for both plasma and RBC EPA). Similarly, in
ANCHOR, the least squares mean change ± SE from baseline to
end-of-treatment in plasma EPA was +159.5 ± 7.0 g/mL with icos-
apent ethyl 4 g/day, +100.5 ± 6.8 g/mL with the 2-g/day dose, and
+8.1 ± 6.6 g/mL with placebo; the corresponding least squares
mean changes in RBC EPA concentrations were +62.8 ± 2.6 g/mL,
+34.6 ± 2.5 g/mL, and +0.4 ± 2.4 g/mL, respectively (P < 0.0001
for each icosapent ethyl dose vs placebo for both plasma and RBC
EPA). The numbers of patients included in this analysis with EPA
results below the LLOQ in plasma and RBCs were 6 and 17 in
60 H.E. Bays et al. / Prostaglandins & other Lipid Mediators 125 (2016) 57–64
Table  1
Demographics.
Characteristic Phase 1 PK Study MARINE ANCHOR
Icosapent
Ethyl
4 g/day
(n = 12)
Icosapent
Ethy
2 g/day
(n = 12)
Icosapen
Ethyl
4 g/day
(n = 77)
Icosapent
Ethyl
2 g/day
(n = 76)
Placebo
(n = 76)
Icosapent
Ethyl
4 g/day
(n = 233)
Icosapent
Ethyl
2 g/day
(n = 236)
Placebo
(n = 233)
Age, mean
(SD), y
37.9
(12.9)
36.9
(13.5)
51.9
(10.3)
53.4
(9.3)
53.4
(8.3)
61.1
(10.0)
61.8
(9.4)
61.2
(10.1)
Men,
n  (%)
6
(50.0)
6
(50.0)
59
(76.6)
58
(76.3)
58
(76.3)
142
(60.9)
144
(61.0)
145
(62.2)
Weight, mean
(SD), kg
75.5
(13.4)
74.5
(14.1)
93.2
(18.3)
92.1
(15.6)
93.0
(16.9)
94.5
(18.3)
95.5
(18.3)
97.0
(19.1)
BMI, mean
(SD), kg/m2
27.2
(2.6)
26.2
(2.6)
30.4
(4.3)
30.8
(4.2)
31.0
(4.3)
32.7
(5.0)
32.9
(5.0)
33.0
(5.0)
Diabetes,
n (%)
NA NA 22
(28.6)
20
(26.3)
21
(27.6)
171
(73.4)
172
(72.9)
171
(73.4)
Statin use,
n (%)
NA NA 20
(26)
19
(25)
18
(24)
Required Required Required
BMI  = body mass index; NA = not applicable; PK = pharmacokinetic; SD = standard deviation.
Table 2
Fasting Triglyceride and EPA Concentrations at Baseline and End of Treatment With Icosapent Ethyl.
Characteristic Phase 1 PK Study MARINE ANCHOR
Icosapent
Ethyl
4 g/day
(n = 12)
Icosapent
Ethyl
2 g/day
(n = 12)
Icosapent
Ethyl
4 g/day
(n = 77)
Icosapent
Ethyl
2 g/day
(n = 76)
Placebo
(n = 76)
Icosapent
Ethyl
4 g/day
(n = 233)
Icosapent
Ethyl
2 g/day
(n = 236)
Placebo
(n = 233)
Plasma triglyceride levels, mg/dL
n = 76 n = 73 n = 75 n = 226 n = 234 n = 227
Baseline,
median (IQR)
NA NA 679.5
(265.3)
656.5
(303.5)
703.0
(426.5)
264.8
(93.0)
254.0
(92.5)
259.0
(81.0)
EOT,
median (IQR)
NA NA 502.0
(302.0)
605.5
(415.0)
745.5
(886.5)
220.8
(92.0)
244.3
(117.0)
269.5
(149.5)
Total plasma EPA levels, g/mL
n  = 9 n = 10 n = 69 n = 62 n = 61 n = 71 n = 73 n = 81
Baseline,
mean  (SD)
19.3
(16.1)
7.9
(7.0)
61.2
(67.4)
63.6
(51.4)
57.7
(42.7)
28.1
(18.8)
28.1
(13.7)
28.1
(28.0)
EOT,
mean (SD)
231.2
(69.0)
108.9
(52.7)
326.7
(205.7)
185.0
(96.9)
52.8
(40.0)
182.6
(71.7)
123.8
(67.8)
30.6
(27.9)
RBC EPA levels, g/mL
n = 9 n = 10 n = 66 n = 61 n = 64 n = 69 n = 71 n = 79
Baseline,
mean  (SD)
12.1
(15.7)
5.7
(4.3)
16.0
(9.2)
15.7
(9.9)
14.7
(9.3)
11.6
(5.6)
10.9
(5.2)
11.2
(6.6)
EOT, 76.2 36.9 71.6 44.9
0.5)
11.6 72.7 43.7 9.9
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OT = end of treatment; EPA = eicosapentaenoic acid; IQR = interquartile range; NA =
ARINE and 5 and 11 in ANCHOR, respectively; these values were
mputed as described in the Methods. In the PK study, there were 7
nd 4 subjects with EPA results below the LLOQ in plasma and RBCs,
espectively (all were baseline values); values for these patients
ere set to zero and were included in the analysis. The numbers
f patients with outlier values that were excluded from analysis of
PA concentrations in plasma and RBC, respectively, were 18 and
0 in MARINE and 11 and 15 in ANCHOR. There were no excluded
ubjects in the PK study due to outlier EPA values.
.3. Relationship between TG-lowering response and EPA
oncentration
Analysis of MARINE and ANCHOR revealed a dose-dependent
eduction in fasting TG levels that was also associated with
ncreases in EPA concentrations (Fig. 4). In MARINE, icosapent
thyl 4 g/day and 2 g/day produced increases in plasma EPA lev-
ls of +679% and +309%, respectively (least squares mean percent
hanges from baseline), which also corresponded with TG level
eductions of −27% and −7%, respectively (median percent change(8.7) (31.5) (16.8) (5.7)
pplicable; RBC = red blood cell; SD = standard deviation; TG = triglyceride.
from baseline). In ANCHOR, icosapent ethyl 4 g/day and 2 g/day
produced increases in plasma EPA levels of +666% and +398%,
respectively (least squares mean percent changes from baseline),
which also corresponded with TG level reductions of −18% and
−6%, respectively (median percent change from baseline). Icos-
apent ethyl produced similar dose-dependent relationships for
the reduction in median TG levels and increase in RBC EPA con-
centrations (Fig. 4). The Spearman correlation coefﬁcients for the
relationship between the TG-lowering response and EPA concen-
tration were −0.22 (P = 0.002) in plasma and −0.34 (P < 0.0001)
in RBCs in MARINE and −0.24 (P = 0.0003) in plasma and −0.33
(P < 0.0001) in RBCs in ANCHOR.
3.4. Factors potentially affecting icosapent ethyl
pharmacokineticsIn the ANCHOR ANCOVA model for percent change from baseline
to week 12 in EPA concentrations in both plasma and in RBCs, the
term for treatment was  statistically signiﬁcant (P < 0.0001), while
the terms for gender, type of statin, and presence of diabetes were
H.E. Bays et al. / Prostaglandins & other L
Fig. 3. Icosapent ethyl dose dependence of RBC fasting EPA concentrations in
the phase 1 PK study in healthy adult volunteers (28 days) and in the MARINE
and ANCHOR studies in adult patients with hypertriglyceridemia (12 weeks).
Mean concentrations are based on baseline-subtracted trough concentrations
of  total EPA (change from baseline) at steady state. *In the PK study, there
was  no placebo group but a value of zero was plotted as a point of refer-
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Hnce. CI = conﬁdence interval; EPA = eicosapentaenoic acid; MARINE = Multi-Center,
lacebo-Controlled, Randomized, Double-Blind, 12-week Study with an Open-Label
xtension; PK = pharmacokinetic.
ot statistically signiﬁcant (P = 0.7884, 0.6342, and 0.4971, respec-
ively, for plasma EPA; P = 0.7910, 0.5353, and 0.4722, respectively,
or RBC EPA).
In the MARINE ANCOVA model for percent change from baseline
o week 12 in plasma EPA concentration, the term for treatment was
tatistically signiﬁcant (P < 0.0001), while the terms for gender and
he use of statin therapy at randomization were not statistically
igniﬁcant (P = 0.4132 and 0.5643, respectively). In the ANCOVA
odel for percent change from baseline to week 12 in RBC EPA
oncentration, the terms for treatment and gender were statisti-
ally signiﬁcant (P < 0.0001 and P = 0.0063, respectively), while the
erm for the use of statin therapy at randomization was not statisti-
ally signiﬁcant (P = 0.8083). Since the gender term was statistically
igniﬁcant for percent change in RBC EPA, the treatment•gender
nteraction was added to the model and least squares means were
alculated, which resulted in a statistically signiﬁcant difference by
ender in the 2 g/day arm (P = 0.0268) and a difference approaching
tatistical signiﬁcance in the 4 g/day arm (P = 0.0789).
The pharmacokinetic assessments in these studies were per-
ormed in the fasting state, just prior to administration of icosapent
thyl with or following a meal or snack. Studies investigating the
harmacokinetics of icosapent ethyl when administered without
ood were not performed.
. Discussion
Icosapent ethyl at doses of 4 g/day and 2 g/day increased trough
PA concentrations in plasma and RBCs compared with baseline in
 dose-dependent manner across 3 clinical studies, indicating that
his agent has predictable pharmacokinetics in healthy volunteers
nd in patients with hypertriglyceridemia. The EPA concentrations
chieved with icosapent ethyl appeared to be similar to or exceed
he total levels of EPA alone or EPA and DHA reported in studies of
ther prescription omega-3 fatty acid products [38]. For example, in
atients with very high TG levels, the trough plasma EPA level mea-
ured at the end of treatment was 327 g/mL with icosapent ethyl g/day in MARINE. In comparison, plasma EPA and DHA levels were
70 g/mL and 169 g/mL, respectively, following treatment with
mega-3-carboxylic acids 4 g/day in the Epanova for Lowering Very
igh Triglycerides (EVOLVE) study in patients with very high TGipid Mediators 125 (2016) 57–64 61
levels [21]. Similarly, in patients with high TG levels, the plasma EPA
concentration was  183 g/mL at end of treatment with icosapent
ethyl 4 g/day in ANCHOR, whereas plasma EPA and DHA concen-
trations were 105 g/mL and 100 g/mL, respectively, following
treatment with omega-3-carboxylic acids 4 g/day in the separate
Epanova Combined With a Statin in Patients With Hypertriglyc-
eridemia to Reduce Non-HDL Cholesterol (ESPRIT) study [39].
The mean trough EPA concentrations in plasma achieved with
icosapent ethyl treatment for 12 weeks in patients with high
TG levels in ANCHOR (2 g/day, 124 g/mL; 4 g/day, 183 g/mL)
and very high TG levels in MARINE (2 g/day, 185 g/mL; 4 g/day,
327 g/mL) appear to be similar to or greater than the 5-year on-
treatment plasma EPA concentration reported in JELIS (1.8 g/day,
170 g/mL), which investigated treatment with another highly
puriﬁed prescription EPA ethyl ester that is approved in Japan but
not in the US [40]. JELIS demonstrated that addition of EPA ethyl
ester 1.8 g/day to low-dose statin therapy signiﬁcantly reduced
major coronary events in hypercholesterolemic Japanese patients.
Although a lower dose of EPA ethyl ester was used in JELIS, base-
line plasma EPA concentrations (97 g/mL) appeared to be notably
higher than those found in ANCHOR, likely reﬂecting high ﬁsh con-
sumption in the Japanese diet. The effect of icosapent ethyl 4 g/day
on cardiovascular outcomes is currently being investigated in high-
risk patients with baseline TG levels of 200–499 mg/dL despite
statin therapy in REDUCE-IT.
This analysis revealed dose-dependent relationships between
plasma and RBC EPA concentrations and the degree of TG level
lowering by icosapent ethyl. These relationships are consistent
with the predictable pharmacokinetic-pharmacodynamic charac-
teristics of icosapent ethyl. Moreover, the pharmacokinetics of
icosapent ethyl based on percent change increases in plasma EPA
was not affected by the use/type of statins and did not appear to be
affected by gender. A treatment•gender interaction was  observed
in the MARINE RBC EPA analysis, but it is difﬁcult to draw any
substantial conclusions regarding the strength of this interaction
considering the small sample size of women in the treatment
arms (13–15 per arm for EPA concentrations) and the lack of a
treatment•gender interaction across plasma EPA in ANCHOR and
MARINE or in RBC EPA in ANCHOR. Evaluation of icosapent ethyl
4 g/day in drug–drug interaction studies of atorvastatin, warfarin,
omeprazole, and rosiglitazone found no drug–drug interactions
[41–44].
The EPA levels measured in the present analyses appeared
to be similar to those previously determined in MARINE and
ANCHOR fatty acid analyses using a gas chromatography/ﬂame ion-
ization detection (GC/FID) method [26,27]. The LC–MS/MS method
used herein permits calculation of EPA concentration in units of
weight/volume (g/mL), whereas the GC/FID method determines
EPA in units of weight/weight (g/g). However, with the latter
method, 28 fatty acids were measured, and expressed plasma EPA
levels as a percentage of total fatty acids. With the 4-g/day dose,
EPA levels (percentage of total fatty acids) increased from 0.5% at
baseline to 3.4% at week 12 in MARINE, and from 0.4% to 3.6% in
ANCHOR [26,27]. The GC/FID method also examined ratios of anti-
inﬂammatory omega-3 fatty acids to pro-inﬂammatory omega-6
fatty acids, including the EPA/AA ratio. Both omega-3/omega-6
fatty acids and EPA/AA ratios increased signiﬁcantly with icosapent
ethyl treatment in MARINE and ANCHOR [26,27]. Although there
were differences in study design, including product administered,
dose, patient populations, and study duration between JELIS and
the MARINE and ANCHOR studies, it may  be worth noting that in
JELIS, higher EPA/AA ratios were associated with decreased risk of
major coronary events; patients with EPA/AA ratios > 0.75 were at
17% lower risk compared with those having ratios < 0.75 (P = 0.031)
[28]. Similarly, and with the same limitations noted above, the
Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for
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oronary Plaque Regression Evaluated by Integrated Backscatter
ntravascular Ultrasonography (CHERRY) study showed a signiﬁ-
ant inverse correlation between plasma EPA/AA ratio levels and
oronary plaque volume (as plasma EPA and EPA/AA ratio levels
ncreased, plaque volume decreased) [45].
This analysis was exploratory in nature. Limitations include
ifferences in populations, study design, dosing regimens, and
uration of treatment between the 3 separate clinical studies
ssessed. An additional limitation is that EPA levels were assessed
t the nominal 5% level with no statistical methods used to control
or the overall error rate. Therefore, results should be interpreted
ith caution and further investigation may  be needed to conﬁrm
hese ﬁndings.
. ConclusionsBased on this post-hoc exploratory analysis of 3 clinical stud-
es, icosapent ethyl produces dose-dependent increases in plasma
nd RBC concentrations of EPA and decreases TG levels. The plasmatween fasting plasma TG level lowering and fasting EPA concentrations in plasma
lacebo-Controlled, Randomized, Double-Blind, 12-week Study with an Open-Label
and RBC concentrations are also dose-dependently related to TG-
lowering efﬁcacy. In patients with high TG levels (≥200 mg/dL),
the end-of-treatment mean plasma and RBC EPA concentrations
were >170 g/mL and >70 g/mL with the icosapent ethyl dose of
4 g/day. Taken together, these ﬁndings indicate that icosapent ethyl
has a predictable pharmacokinetic-pharmacodynamic proﬁle.
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